ClinConnect ClinConnect Logo
Search / Trial NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

Launched by BAYSIDE HEALTH · Aug 25, 2011

Trial Information

Current as of June 20, 2025

Completed

Keywords

Postoperative Fluid Surgery Anaesthesia Fluid Mortality Morbidity

ClinConnect Summary

The investigators have completed a pilot study of 82 subjects to test the feasibility of the trial (2011), and are currently doing a cost-effectiveness substudy (2012-13)

1. AIM OF THE TRIAL To investigate the effectiveness of fluid restriction (vs. liberal), and the possible effect-modification of goal-directed therapy (eg. oesophageal Doppler, Flotrac®). The first will be randomly assigned; the latter will be measured covariates according to local practices and beliefs.

The optimal fluid regimen and haemodynamic (or other) targets for patients undergoing major surgery are based on ratio...

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • 1. Adults (≥18 years) undergoing elective major surgery and providing informed consent
  • 2. All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
  • 3. At increased risk of postoperative complications, defined as at least one of the following criteria:
  • age ≥70 years
  • known or documented history of coronary artery disease
  • known or documented history of heart failure
  • diabetes currently treated with an oral hypoglycaemic agent and/or insulin
  • preoperative serum creatinine \>200 µmol/L (\>2.8 mg/dl)
  • morbid obesity (BMI ≥35 kg/m²)
  • preoperative serum albumin \<30 g/L
  • anaerobic threshold (if done) \<12 mL/kg/min
  • * or two or more of the following risk factors:
  • ASA 3 or 4
  • chronic respiratory disease
  • obesity (BMI 30-35 kg/m²)
  • aortic or peripheral vascular disease
  • preoperative haemoglobin \<100 g/L
  • preoperative serum creatinine 150-199 µmol/L (\>1.7 mg/dl)
  • anaerobic threshold (if done) 12-14 mL/kg/min
  • Exclusion Criteria
  • 1. Urgent or time-critical surgery
  • 2. ASA physical status 5 - such patients are not expected to survive with or without surgery, and their underlying illness is expected to have an overwhelming effect on outcome (irrespective of fluid therapy)
  • 3. Chronic renal failure requiring dialysis
  • 4. Pulmonary or cardiac surgery - different pathophysiology, and thoracic surgery typically have strict fluid restrictions
  • 5. Liver resection - most units have strict fluid/CVP limits in place and won't allow randomisation
  • 6. Minor or intermediate surgery, such as laparoscopic cholecystectomy, transurethral resection of the prostate, inguinal hernia repair, splenectomy, closure of colostomy - each of these are typically "minor" surgery with minimal IV fluid requirements, generally low rates of complications and mostly very good survival.

About Bayside Health

Bayside Health is a leading clinical trial sponsor dedicated to advancing medical research and innovation through rigorous and ethical study design. With a focus on improving patient outcomes, Bayside Health collaborates with healthcare professionals, researchers, and institutions to conduct high-quality clinical trials across a diverse range of therapeutic areas. Committed to transparency and regulatory compliance, the organization prioritizes patient safety and data integrity, ensuring that all trials contribute valuable insights to the medical community and enhance the development of new treatments.

Locations

Melbourne, Victoria, Australia

Patients applied

0 patients applied

Trial Officials

Paul S Myles, MB.BS, MPH, MD, FANZCA

Study Chair

Alfred Hospital, Monash University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials